Media Advisory - Novo Nordisk confirms stable Ozempic® supply across Canada
MISSISSAUGA, ON, Sept. 18, 2026 /CNW/ -- With increased demand for semaglutide, and limited supply of generic options,1,2 Novo Nordisk is confirming an established supply of Ozempic® across Canada. Ozempic® was approved by Health Canada in 2018, and there are now more than one million Canadians using semaglutide.
"Our company remains dedicated to supporting the ongoing health and well-being of Canadians who rely on our medicines," said Iain Graham, General Manager at Novo Nordisk. "Patients have options, and when they choose Ozempic®, we are ready to meet their needs. We are committed to our patients, healthcare providers and our healthcare system, and prioritizing a stable and continuous supply of high-quality medications, including semaglutide, to support Canadians."
About Ozempic®3
Ozempic® is indicated for the once-weekly treatment of adult patients with type 2 diabetes to improve glycemic control. Ozempic® can be used with metformin, sulfonylurea and a sodium-glucose cotransporter 2 inhibitor (SGLT2i) and basal insulin with metformin. Ozempic® is also indicated:
- as an adjunct to diet, exercise, and standard of care to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease.
- to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
For information about Ozempic®, including important safety information, please view the product monograph here.
Eligible Canadians with private drug coverage - as well as those paying entirely out-of-pocket - who choose Ozempic® can access savings through the Ozempic® Savings Card at pharmacies across Canada, excluding Quebec. Savings are also applied automatically through Novo Nordisk Care® Rx operated by Rexall and select online telehealth and retail partners. Additional information on eligibility and access is available at Ozempic.ca.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.ca, Facebook, Instagram, X, LinkedIn and YouTube.
References |
_____________________________ |
3 Novo Nordisk Canada Inc. (April 14, 2026). Ozempic® Product Monograph. |
SOURCE Novo Nordisk Canada Inc.
Contact for further information: Kate Hanna, 905-301-7334, [email protected]; Laura Espinoza, 437-233-6796, [email protected]
Partager cet article